Lymphome T cutané épidermotrope cytotoxique CD8+ « agressif » : difficultés de prise en charge chez un malade atteint d'une dystrophie myotonique de Steinert

The treatment of primary cutaneous epidermotropic CD8+ cytotoxic T-cell lymphoma is not codified. CHOP chemotherapy is usually the first-line therapy but relapses are frequent with median survival of no more than 34 months. In our patient, an additional difficulty was the cardiac toxicity of cytostatic drugs linked to the myopathy which prevented the use of high dosages, requiring a change of therapeutic regimen.